The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CAPR | -67.68% | +33.72% | +5.98% | -86% |
| S&P | +11% | +85.61% | +13.15% | +266% |
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
No news articles found for Capricor Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.49M | -126.0% |
| Gross Margin | 96.62% | -0.8% |
| Market Cap | $329.62M | -33.4% |
| Market Cap / Employee | $2.06M | 0.0% |
| Employees | 160 | 56.9% |
| Net Income | -$24.57M | -95.7% |
| EBITDA | -$25.79M | -103.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $19.51M | -71.5% |
| Accounts Receivable | $0.06M | -85.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.42M | 242.5% |
| Short Term Debt | $3.50M | 329.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -74.74% | -22.3% |
| Return On Invested Capital | -75.10% | 9.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.70M | -102.5% |
| Operating Free Cash Flow | -$19.69M | -69.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.15 | 2.97 | 3.55 | 3.14 | -65.06% |
| Price to Sales | 27.58 | 24.94 | 33.89 | 29.61 | 36.67% |
| Price to Tangible Book Value | 8.15 | 2.97 | 3.55 | 3.14 | -65.06% |
| Enterprise Value to EBITDA | -63.85 | -11.92 | -12.32 | -9.65 | -71.15% |
| Return on Equity | -48.2% | -75.4% | -120.2% | -107.8% | 5.03% |
| Total Debt | $4.83M | $4.63M | $4.42M | $17.92M | 256.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
